Teva storms through second quarter
This article was originally published in Scrip
Executive Summary
The second quarter proved to be a record-breaker for Teva Pharmaceutical Industries with its strongest net sales performance and robust US revenues. Net sales of $2.8 billion (+18%) underlined a successful quarter with net profits of $539 million (+5%).